CRISPR Therapeutics AG Statistics

Total Valuation

LON:0VRQ has a market cap or net worth of GBP 3.26 billion. The enterprise value is 2.06 billion.

Market Cap	3.26B
Enterprise Value	2.06B

Important Dates

The next estimated earnings date is Tuesday, August 5, 2025.

Earnings Date	Aug 5, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	91.75M
Shares Outstanding	n/a
Shares Change (YoY)	+6.74%
Shares Change (QoQ)	+0.56%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	91.33M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	111.70
PB Ratio	2.30
P/TBV Ratio	2.30
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-6.91
EV / Sales	75.03
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-8.66

Financial Position

The company has a current ratio of 15.64, with a Debt / Equity ratio of 0.12.

Current Ratio	15.64
Quick Ratio	15.53
Debt / Equity	0.12
Debt / EBITDA	n/a
Debt / FCF	-0.71
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -19.71% and return on invested capital (ROIC) is -13.58%.

Return on Equity (ROE)	-19.71%
Return on Assets (ROA)	-12.88%
Return on Invested Capital (ROIC)	-13.58%
Return on Capital Employed (ROCE)	-23.18%
Revenue Per Employee	74,199
Profits Per Employee	-759,528
Employee Count	393
Asset Turnover	0.02
Inventory Turnover	n/a

Taxes

In the past 12 months, LON:0VRQ has paid 3.07 million in taxes.

Income Tax	3.07M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -6.85% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-6.85%
50-Day Moving Average	39.62
200-Day Moving Average	43.25
Relative Strength Index (RSI)	75.24
Average Volume (20 Days)	13,091

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	8.26

Income Statement

In the last 12 months, LON:0VRQ had revenue of GBP 29.16 million and -298.49 million in losses. Loss per share was -3.50.

Revenue	29.16M
Gross Profit	-309.66M
Operating Income	-367.18M
Pretax Income	-295.42M
Net Income	-298.49M
EBITDA	-352.35M
EBIT	-367.18M
Loss Per Share	-3.50

Full Income Statement

Balance Sheet

The company has 1.44 billion in cash and 169.78 million in debt, giving a net cash position of 1.27 billion.

Cash & Cash Equivalents	1.44B
Total Debt	169.78M
Net Cash	1.27B
Net Cash Per Share	n/a
Equity (Book Value)	1.42B
Book Value Per Share	16.39
Working Capital	1.35B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -237.21 million and capital expenditures -1.07 million, giving a free cash flow of -238.28 million.

Operating Cash Flow	-237.21M
Capital Expenditures	-1.07M
Free Cash Flow	-238.28M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-1,259.20%
Pretax Margin	-1,013.10%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

LON:0VRQ does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.74%
Shareholder Yield	n/a
Earnings Yield	-9.16%
FCF Yield	-7.32%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0VRQ has an Altman Z-Score of 6.88 and a Piotroski F-Score of 1.

Altman Z-Score	6.88
Piotroski F-Score	1